Related Experiment Video
Updated: Aug 16, 2026
![Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F67458.jpg&w=3840&q=50)
Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
Published on: January 24, 2025
Flocor (CytRx Corp)
1ALZA Corp, PO Box 10950, Palo Alto, CA 94303-0802, USA. nishit.modi@alza.com
Abstract:
CytRx is developing Flocor, an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury 1. It is currently undergoing phase III clinical trials for the treatment of sickle cell crisis. Flocor has rheologic, cytoprotective, anti-adhesive and antithrombotic effects and has potential in the treatment of acute ischemic vascular disorders such as stroke and myocardial infarction (MI). A US NDA is planned for filing in late 1999 or 2000. Flocor is a highly purified form of the nonionic surfactant poloxamer 188, composed of a central block of hydrophobic poly(oxypropylene) units flanked by chains of hydrophilic poly(oxyethylene) units. It has superseded RheothRx (commercial grade poloxamer 188) because of its more favorable therapeutic index. The FDA has informed CytRx that data generated with RheothRx can be used to support an NDA for Flocor.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
FDA Approved Drugs: Changes to Approved Drugs
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Ophthalmic Drug Delivery Systems
Drug Regulation
